Searching to replenish its drug pipeline, Japan's Mitsubishi Tanabe Pharma Corp. has "zeroed in" on NeuroDerm Ltd.'s promising stable of CNS assets, offering to buy the Israeli target for $1.1bn in cash, a price some analysts think will ensure no competing counter-offers materialize.
Terms of the transaction, backed unanimously by NeuroDerm’s board of directors, is $39 per share in cash, implying an equity value of some $1